Brief: Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results In Western And Asian Patients In Updated Analysis From Global Phase III HARMONi Study
22/07/2026 12:21
BRIEF-Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results In Western And Asian Patients In Updated Analysis From Global Phase III HARMONi Study July 22 (Reuters) - Summit Therapeutics Inc SMMT.O:
IVONESCIMAB PLUS CHEMOTHERAPY SHOWS CONSISTENT, FAVORABLE OVERALL SURVIVAL RESULTS IN WESTERN AND ASIAN PATIENTS IN UPDATED ANALYSIS FROM GLOBAL PHASE III HARMONI STUDY
SUMMIT THERAPEUTICS - IVONESCIMAB PLUS CHEMOTHERAPY SHOWS POSITIVE OS TREND IN ASIAN AND WESTERN PATIENTS
SUMMIT THERAPEUTICS - PHASE III HARMONI STUDY SHOWS STATISTICALLY SIGNIFICANT PFS BENEFIT
SUMMIT THERAPEUTICS - IVONESCIMAB CONTINUES TO SHOW ACCEPTABLE SAFETY PROFILE; NO NEW SAFETY SIGNALS
SUMMIT THERAPEUTICS - FDA ACCEPTS BLA FOR IVONESCIMAB; PDUFA DATE NOVEMBER 14, 2026
Source text: ID:nBw8kR4BPa
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)